Exelixis

Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says
Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says
Fierce Pharma
Carbometyx
Exelixis
clinical trials
neuroendocrine tumors
Flag link:
Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial
Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial
BioSpace
Eli Lilly
Retevmo
thyroid cancer
medullary thyroid cancer
clinical trials
Exelixis
Capometyx
Sanofi
Caprelsa
Flag link:
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Exelixis
Ipsen
Carbometyx
prostate cancer
Flag link:
Exelixis, Teva settle Cabometyx patent litigation with 2031 generic license
Exelixis, Teva settle Cabometyx patent litigation with 2031 generic license
Fierce Pharma
Exelixis
Teva Pharmaceutical
patents
legal
Cabometyx
cancer
Flag link:
Exelixis Advances Board Refreshment Plan
Exelixis Advances Board Refreshment Plan
Businesswire
Exelixis
Flag link:
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Roche
Exelixis
renal cell carcinoma
Tecentriq
Cabometyx
clinical trials
Flag link:
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Fierce Pharma
Roche
Tecentriq
Exelixis
Cabometyx
clinical trials
non small cell lung cancer
Flag link:
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Endpoints
Exelixis
Cabometyx
Tecentriq
metastatic non-small cell lung cancer
clinical trials
Flag link:
Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent
Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent
BioSpace
Exelixis
Catalent
antibody-drug conjugate
Flag link:
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Flag link:
ADC Space Continues to Thrive with Four More Companies Linking Up
ADC Space Continues to Thrive with Four More Companies Linking Up
BioSpace
antibody-drug conjugate
Exelixis
Bioinvent
Oxford BioTherapeutics
Immunogen
Flag link:
Exelixis taps into cancer antibody discoverer out of Sweden
Exelixis taps into cancer antibody discoverer out of Sweden
Endpoints
Exelixis
Bioinvent
cancer
Sweden
immuno-oncology
Flag link:
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Endpoints
Exelixis
Cabometyx
liver cancer
clinical trials
Flag link:
What Novartis could buy with its windfall
What Novartis could buy with its windfall
EP Vantage
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Flag link:
Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout
Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout
Endpoints
ESMO
Exelixis
thyroid cancer
Cabometyx
Flag link:
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
Fierce Pharma
ESMO
Exelixis
Cabometyx
Roche
Tecentriq
clinical trials
prostate cancer
Flag link:
Exelixis stunned by death of Chief Medical Officer Schwab, sales lead Berndt
Exelixis stunned by death of Chief Medical Officer Schwab, sales lead Berndt
Fierce Biotech
Exelixis
executives
Flag link:
In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
Fierce Pharma
Exelixis
Cabometyx
liver cancer
Bayer
Nexavar
Flag link:
Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis
Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis
Endpoints
Exelixis
Cabometyx
Roche
Tecentriq
prostate cancer
Flag link:
ASCO 2021: Watch for Sanofi/Sloan Kettering, Incyte, Exelixis and AstraZeneca
ASCO 2021: Watch for Sanofi/Sloan Kettering, Incyte, Exelixis and AstraZeneca
BioSpace
ASCO 2021
Sanofi
Sloane Kettering
Incyte
AstraZeneca
Exelixis
oncology
Flag link:

Pages